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Dissertation summary 
African horse sickness (AHS) is a viral disease of equids caused by the African horse 
sickness virus (AHSV), a double-stranded RNA virus of the genus Orbivirus. The 
disease had a devastating effect on the sporting horse industry, and many 
communities who rely on equids for subsistence farming. 
In this study, which started in 2016, blood samples were collected from 81 horses in 
the KwaZulu Natal province of South Africa.  Six horses (7%) were identified as AHSV 
positive and had their viral load quantified using a standard RT-qPCR assay. A semi-
quantitative method, using digital gel image analysis, was evaluated as an alternative 
to qPCR in resource-limited settings. A significant correlation was found in the 
quantification data obtained using qPCR and digital gel analysis (P < 0.01), 
demonstrating the potential for its use in under-equipped diagnostic laboratories. 
Vaccination is currently the main tool for control of AHS in endemic areas. Live 
attenuated vaccines (LAV) have the potential to disrupt effective disease monitoring 
by being a source of the detectable virus. The sensitivity of nucleic acid diagnostic 
assays allows for the detection of low levels of AHSV prior to the onset of clinical signs. 
A study was conducted on the effect that this vaccine has on viraemia levels and the 
disruptive effect this may have is discussed. Routinely vaccinated miniature mares 
(n=9) had their AHSV viraemia levels monitored following the use of a commercial 
polyvalent LAV. No AHSV was detected in the horses following vaccination. The 
absence of AHSV in the mares supports the concept that multiple vaccinations reduce 
the risk of vaccine-induced viraemia. 
Flinders Technology Associates® filter paper cards (FTA® cards) are designed to store 
nucleic acid from fresh sample material in a stable matrix and may be a practical 
solution to disease surveillance in resource-limited settings, where conventional 
sampling methods are not always suitable. Storage and elution conditions of AHSV 
RNA from these cards have yet to be investigated. This study compared the efficacy 
of two elution reagents for AHSV RNA extraction from blood applied to FTA® cards. 
Cards with AHSV positive blood applied were stored at room temperature for one 
week. Amplified products were extracted using TE-buffer with an elution time of 24 
hours. This study shows that FTA® cards are feasible for AHSV nucleic acid assays 
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but further investigation into standardised procedures for the storage and recovery of 
AHSV RNA from FTA® cards is required. 
The AHSV genome is made up of ten double-stranded RNA segments with nine 
antigenically different serotypes of AHSV identified so far. However, there is limited 
information on the serotype prevalence of AHSV in endemic areas. Therefore, 
multivalent vaccines remain the mainstay for disease control in these regions. 
Improved epizootiological information can improve vaccination programs and control 
mechanisms. In this experiment, a novel approach was investigated for the 
assessment of AHSV nucleic acid variations using high-resolution melt 
analysis (HRMA).  Blood infected with a wild strain of AHSV was used in a PCR that 
targeted regions of Segment 10 (S10) and Segment 2 (S2). Following this, high-
resolution melting curves were generated from these PCR products. S10 primers 
amplified the expected 181 bp product but the other primer sets failed to amplify the 
S2 gene segment, warranting further evaluation and optimisation of the primer sets 
used to detect currently circulating AHSV strains. 
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DISSERTATION INTRODUCTION 
African horse sickness (AHS) is an arthropod-borne disease causing high levels of 
mortality primarily affecting members of the Equidae family. This disease occurs in one 
of four forms distinguished by its clinical symptoms. Due to the range of clinical 
symptoms and similarities to other equine diseases, a laboratory diagnosis of AHS is 
necessary (OIE, 2017). AHS is a controlled and notifiable disease in South Africa (Act 
35 of 1984) and is listed as notifiable by the World Organisation for Animal Health 
(OIE). There is no cure for AHS, and control relies on vaccination, vector management 
and effective control strategies.  
AHS is caused by the African horse sickness virus (AHSV), an Orbivirus in the 
Reoviridae family. There are currently nine antigenically different serotypes of AHSV 
with limited cross-protection between serotypes, all of which are considered endemic 
in sub-Saharan Africa, (Howell, 1962; von Teichman et al., 2010).  
Major outbreaks have occurred in North Africa, Asia and Europe (Mellor & Hamblin, 
2004). These outbreaks have caused devastating losses to the equine industry both 
because of the disease, and because of the negative impact it has on the growth of 
the equine industry due to the mandatory implementation of strict quarantine 
procedures. In addition to the significant impact AHS has on the South African 
racehorse and sporting horse industry, AHS affects a large population of mostly 
unvaccinated equids which are relied on for transport and draught power in rural areas.  
Control of AHS is limited to vaccination, and vector and movement control because 
there is no cure for the disease (Zientara et al., 2015). Advancements in the accuracy, 
speed and affordability of diagnostic techniques for AHS will improve disease 
surveillance and the timely implementation of control strategies in endemic areas 
(Weyer et al., 2015). 
The research presented in this dissertation aimed to address several aspects related 
to the molecular diagnostics of AHS: To review and summarise the available literature 
pertaining to AHS molecular diagnostics; to investigate the potential disruptive effect 
the vaccine has on disease surveillance; to assess alternative methods for sampling 
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and quantification of AHSV in resource-limited areas; and, lastly, to generate high 
resolution melt data on current AHSV strains as part of a potential serotyping assay.  
 
Research objectives 
The specific goals of this study were to: 
• Collect and identify AHS positive blood samples in the KwaZulu-Natal 
province to obtain wild-type AHSV strains for subsequent analysis. 
• Evaluate the use of digital gel analysis as a quantitative alternative to qPCR 
in resource-limited settings. 
• Investigate the level of viraemia induced in mares by a commercial live 
attenuated vaccine using a standard qPCR assay to assess the impact this 
has on disease surveillance. 
• Evaluate a protocol for extracting viable AHSV RNA for PCR amplification 
using dried blood spot filter paper technology as an alternative to 
conventional sampling methods which require stringent storage conditions. 
• Develop a protocol for the use of high-resolution melts for a potential 
serotyping assay, using currently circulating strains of AHSV. 
 
The referencing system used in the chapters of this dissertation follows the specific 
style used in the South African Journal of Animal Science.  
The dissertation is in the form of discrete research chapters, each following the format 
of a stand-alone research paper. This is the dominant thesis format used by the 
University of KwaZulu-Natal as it facilitates the publishing of research from work more 
easily than a single document. As such, there is an unavoidable repetition of references 
and introductory information between chapters.  
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CHAPTER 1:  
Literature review 
1.1. Introduction 
African horse sickness (AHS) is a severe viral disease affecting members of the 
Equidae family (OIE, 2013). AHS is a notifiable disease as classified by the 
World Organisation for Animal Health (OIE) due to the severe effect that it has on the 
equine industry, with high mortality rates (OIE, 2013). AHS has a significant impact on 
the South African racehorse and performance horse industries, as well as affecting 
many susceptible rural equids. Fully susceptible horses have up to 90% mortality rate, 
while zebra and donkeys rarely show clinical signs (Erasmus, 1972). 
AHS is caused by the African horse sickness virus (AHSV), a double-stranded RNA 
virus of the Orbivirus genus from the Reoviridae family (Verwoerd et al., 1979). Nine 
antigenically distinct serotypes of AHSV (AHSV-1 to AHSV-9) have been isolated, the 
last of which was described by Howell in 1962.  AHSV is classified as an arbovirus due 
to its ability to infect and multiply within haematophagous arthropods (Mellor, 2000). 
AHS is a vector-borne disease spread by members of the Culicoides species (biting 
midges), with Culicoides imicola (Diptera: Ceratopogonidae) being the most significant 
vector species in South Africa. The disease is most prevalent in warm, wet weather 
when the Culicoides vectors are most abundant. However, Culicoides spp. are found 
throughout winter in many endemic areas (Venter et al., 2014). Culicoides spp. capable 
of spreading AHSV have been found worldwide, forcing strict quarantine protocols to 
be implemented by the European Union governing equid movement (European 
Commission, 2008).  
Climate change is proposed as a driving force for the emergence of Bluetongue 
virus (BTV) in Europe because of the strong link between the epizootiology and the 
growing number of suitable habitats for the vector (Guis et al., 2012). This virus is 
closely related to AHSV, sharing many similarities, including being vectored by the 
Culicoides spp. There is an increasing concern that the introduction of AHSV into 
Europe may result in its permanent establishment due to the already present vector 
species and endemic nature of BTV (Allison et al., 2009; Thompson et al., 2012). 
Vaccines are currently used annually in endemic areas and a stockpile of vaccines 
exists to manage an outbreak in Europe. The risk of the live vaccine reverting to 
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virulence makes this vaccine an unattractive option for Europe, where the entire equine 
population is susceptible (Savini et al., 2017). This concern is justified by a published 
case of vaccine virus reversion to virulence in South Africa in 2014 (Weyer et al., 2016). 
Therefore, the possibility of vaccine-induced viraemia and the disruptive effect that it 
may have on molecular disease surveillance has been explored in this research.  
1.2. Epizootiology 
AHSV is widely spread in sub-Saharan Africa, extending as far north as the Sahara 
Desert, which provides a barrier between southern and northern Africa (Mellor & 
Hamblin, 2004). Each of the nine serotypes of AHSV are found throughout, and are 
considered to be endemic, in Southern Africa. Since 2007, serotypes 2 and 7 have 
been found in West and East Africa, where only serotype 9 had been found previously 
(Zientara et al., 2015).  
Beyond South Africa, Spain has had five outbreaks of AHS starting in 1966 that were 
caused by serotype 9. There was no sign of the virus in Europe for 20 years prior to 
the AHSV-4 discovery in Spain. Along with three additional outbreaks, these outbreaks 
were reported to have been caused by subclinical zebra imported from Namibia 
(Lubroth, 1988). Strict vaccination programs, using monovalent vaccines and animal 
control measures, eliminated the disease from the region after persisting for four years. 
In total, over 1300 horses died because of the Spanish AHS outbreaks (Mellor, 1993). 
Such outbreaks have resulted in the implementation of strict equine movement 
restrictions from endemic areas. 
The international exportation of horses from South Africa to non-endemic countries is 
required from the AHS free zone in the Western Cape (Fig. 1.1.). This area has been 
declared AHS-free and exports can occur from this region, on condition that it is 
preceded by strict surveillance. The surveillance zone borders the AHS-free zone and 
is constantly monitored for controlled equine diseases. Outbreaks in the surveillance 
zone disrupt the international exportation of horses from South Africa, negatively 
impacting the equine industry. Recently, there have been AHS positive cases in the 
surveillance zone, with outbreaks of AHSV-1 in both Mamre in 2011 and Paarl in 2016 
(Weyer et al., 2017). 
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Figure 1.1 - Map showing the infected, protection, surveillance and free zones for 
African Horse sickness in South Africa (Western Cape Government, 2014). 
Several orbivirus diseases in the northern hemisphere are transmitted by AHSV 
vectors (Howell et al., 2004). Together with the global spread of BTV, this has raised 
concerns of potential AHSV outbreaks outside of Africa and generated interest in 
assessing the potential impact of AHS outbreaks internationally (MacLachlan & 
Guthrie, 2010; Thompson et al., 2012; Chapman et al., 2017). Strict animal movement 
control is critical to prevent entry of AHSV into non-endemic regions. 
1.3. Host Range 
Horses, mules, zebra and donkeys are the most common hosts for AHSV (Zientara et 
al., 2015). The mortality rate in horses is as high as 90% but fully recovered horses do 
not continue to be carriers of the virus (Coetzer & Guthrie, 2004). In zebra and 
donkeys, the disease usually remains subclinical and has a lower mortality rate 
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(Coetzer & Erasmus, 1994). Viral reservoirs allow for the permanent establishment of 
the virus and are important to the epizootiology of these diseases. 
Zebra have been suggested as a reservoir for AHSV due to their low mortality and, 
therefore, caution is advised when relocating zebra to non-AHS endemic areas 
because zebra can create suitable conditions for AHSV (Barnard, 1998). The 
emergence of AHSV in West Africa, where zebra are not present, suggests the role of 
other species as reservoir hosts in these areas. Donkeys are unlikely to be long-term 
reservoirs for AHS as they have been shown to develop only a short period of viraemia 
following AHSV challenge (Hamblin et al., 1998). Dogs have also been shown to be 
susceptible to AHS by ingestion of infected meat and experimental infection (Theiler, 
1910; Van Rensberg et al., 1981). It is generally accepted that dogs do not play a role 
in the spread of AHS, but a positive case of AHS in a dog through natural infection via 
a non-oral route was confirmed by Van Sittert et al. (2013). 
Humans are not susceptible to natural infection of field strains of AHSV, although some 
neurotropic vaccine strains have caused encephalitis in humans and are consequently 
no longer in production (Swanepoel et al., 1992). 
1.4. Vector 
AHSV was initially suspected to have been transmitted through haematophagous 
arthropods but the exact species was not identified until 1944 when field-collected 
Culicoides were shown to carry the virus (Du Toit, 1944). Anopheles mosquitoes have 
been studied (Theiler, 1903; Mellor, 1994), but only the Culicoides spp. have been 
found to have a significant effect on the epizootiology of the disease (Mellor, 1994). 
The adult female C. imicola is the primary vector of AHSV in sub-Saharan Africa 
(Fig 1.2) (Mellor, 1994).  
There are currently over 1400 known species of Culicoides, with 30 species of 
Culicoides thought to play some role in the transmission of BTV (Meiswinkel et al., 
2004).  Due to the similarities of BTV to AHS, there are concerns that BTV vectors 
found globally could spread AHS, and that currently established populations of 
Culicoides in AHS-free areas could cause a severe outbreak (Robin et al., 2016). 
Culicoides bolitinos (Diptera: Ceratopognidae) is morphologically similar to C. imicola 
and can also vector AHSV (Meiswinkel & Paweska, 2003). The larvae and pupae of 
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C. bolitinos inhabit the dung of cattle which brings additional risks to horses on cattle 
farms. Importantly, C. bolitinos will readily enter a stable to feed, reducing the efficacy 
of stabling as preventing contact between host and vector (Meiswinkel et al., 2000).  
Following the Spanish AHSV outbreak, isolates of C. obsoletus and C. pulicaris tested 
positive for AHSV and may have been important vectors during this outbreak (Mellor, 
1994). These midge species are endemic in northern and western Europe, and their 
ability to transfer AHSV create the requisite conditions for outbreaks of the disease. 
The midges’ ability to move a few kilometres from their breeding sites to feed 
emphasises the importance of movement control. In extreme cases, strong winds can 
carry midges much greater distances and have probably carried AHSV across the 
Strait of Gibraltar from Africa to Europe (Pedgley & Tucker, 1977). 
The characteristics of the Culicoides vector are linked with the epizootiology of AHSV. 
The distribution of C. imicola has been demonstrated to be closely linked to the soil 
type, especially high-clay, moisture-retaining soils (Meiswinkel, 1998). Climatic 
conditions such as high levels of rainfall increase the number of breeding sites for the 
midge and outbreaks of AHS have often occurred when there has been heavy rainfall 
following a drought because increased breeding sites for the vector, combined with a 
high concentration of animal hosts at drinking holes, facilitated the rapid transmission 
of the virus (Jenkins & Young, 2010).  
 
Figure 1.2 - Female Culicoides after feeding (Jenkins, 2008).  
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1.5. Description of the virus 
The AHSV is a member of the Orbivirus genus of the Reoviridae family. Orbiviruses 
are non-enveloped viruses with ten double-stranded RNA segments coding for 11 viral 
proteins (VP) (Calisher & Mertens, 1998). The coding system used in this work, 
described by Mertens et al. (2006), is presented in Table 1.1. 
Table 1.1 - Coding assignment and size of genome segments from Mertens et 
al. (2006) 
Genome segment Coding assignment  
(Mertens et al., 2006) 
Size (bp) 
(Mertens et al., 2006) 
1 VP1 3965 
2 VP2 3205 
3 VP3 2792 
4 VP4 1978 
5 NS1 1748 
6 VP5 1566 
7 VP6 1169 
8 VP7 1167 
9 NS2 1166 
10 NS3/NS3a 756 
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The virus has seven structural proteins (VP1-7) organised in a two-layer capsid (Fig. 
1.3). 
 
Figure 1.3 - Diagram of orbivirus structure showing structural proteins (Wilson et al., 
2009) 
The core particle of the virus is composed of major proteins, VP3 and VP7, and minor 
proteins, VP1, VP4 and VP6. The outer capsid is comprised of VP2 and VP5 (Bremer 
et al., 1990, Roy et al., 1994). The outer capsid protein, VP2, differs most between 
serotypes and is responsible for the antigenic diversity of the virus and as a result, is 
often the target for type-specific nucleic acid-based assays (Roy et al., 1994). Segment 
10 (S10) encodes for the non-structural proteins, NS3/NS3a, which are involved with 
the release of virus from infected cells (Martin et al., 1998).  Phylogenetic studies into 
AHSV S10 have found homology in S10 from different serotypes, allowing serotypes 
to be grouped genotypically into one of three groups using this segment (Martin et al., 
1998; Groenink, 2009).  
So far, nine antigenically different serotypes of AHSV have been identified. The last of 
these serotypes were isolated in 1960, suggesting a degree of viral stability (Howell, 
1962). This is important for the effective control of viral diseases because vaccines are 
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required to be updated in line with currently circulating serotypes (Mumford, 2007). The 
frequent emergence of new serotypes complicates this task. Genetic drift of AHSV was 
investigated by Groenink (2014) using phylogenetic analyses on available virus 
sequences at the time. Little to no genetic drift in AHSV sequences from 1960s-2000s 
was demonstrated. This is different to BTV, which has 28 serotypes, four of which have 
been identified in the last decade (Hofmann et al., 2008; Zientara et al., 2014; Sun et 
al., 2016; Savini et al., 2017).  
 
Reassortment is a system of genetic recombination which occurs in segmented RNA 
viruses. The segmented genome structure allows for segments of different viral strains 
to be exchanged during co-infections (McDonald et al., 2016). To date, there have 
been no reported cases of a multiple serotype co-infection for AHSV but a reverse 
genetics study showed that co-infection with two AHSV serotypes resulted in 
reassortment (Matsuo et al., 2010). Live attenuated vaccines, as in the case with the 
AHS vaccine, contain multiple serotypes and may create suitable conditions for 
vaccine virus reassortment. 
 
1.6. Control 
1.6.1. Treatment 
There is currently no prescribed treatment for AHS. Control of the spread of the disease 
is considered the best prophylactic means of minimising the impact of AHS (Zientara 
et al., 2015). 
1.6.2. Vector control 
Vector control is one of the many approaches taken to reduce AHS transmission. The 
wide-ranging characteristics and sheer numbers of the Culicoides vectors add to the 
multifaceted problem of AHS.  
 
Midge numbers are positively correlated with increasing ground moisture levels and 
sunlight (Jenkins, 2008). Larvicidal application at these breeding sites can decrease 
midge number in the area by eliminating the immature life stage of the vector (Page et 
al., 2014). Improving drainage of marshlands and standing water are environmental 
changes that can reduce the number of vectors in an area (Carpenter et al., 2008).  
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Other strategies to reduce transmission include contact restriction between host and 
vector through stabling of horses. While stabling is effective against C. imicola, it does 
not deter all Culicoides spp., and C. bolitinos will readily enter a stable to feed 
(Meiswinkel et al., 2000).  
The efficacy of these strategies depends on good husbandry and persistent application 
of these measures, particularly during outbreaks and in favourable vector conditions. 
1.6.3. Vaccination 
Prior to 1930, vaccination was done by introducing virulent AHSV simultaneously with 
sera containing antibodies for AHSV (Theiler, 1915). The antibodies contained within 
the sera may have been intended for a different serotype or insufficient for the viral 
load, resulting in high animal mortality (Mellor & Hamblin, 2004). Virus attenuation for 
vaccine production was initially developed using suckling mouse brain passage but 
has since been changed to cell culture passage (Mellor & Hamblin, 2004).  
Onderstepoort Biological Products (OPB) have produced a polyvalent, cell-cultured 
live attenuated vaccine (LAV) since 1994 (Fig. 1.4). This is the most commonly 
administered vaccine in most endemic areas. The vaccine is given in two doses 4 
weeks apart. Dose 1 contains serotypes 1,3,4 and Dose 2 has serotypes 2,6,7,8. Two 
serotypes are not included in the multivalent LAV: AHSV-5 because of reports of 
deaths in vaccinated animals; and AHSV-9 because of cross-protection with AHSV-6 
and its low occurrence in Southern-Africa (von Teichman et al., 2010). Horses may not 
move into AHS controlled areas less than 60 days after the second vaccination. This 
is because of the potential for the vaccine virus to be transmitted to serologically naïve 
animals within these areas (Weyer et al., 2016). 
The use of the LAV presents a challenge when using nucleic-acid based detection 
techniques for diagnosis, primarily because most RT-PCR assays are unable to 
distinguish between the LAV-virus and wild virus strains (Weyer et al., 2017). 
Therefore, vaccinated animals may test positive if the vaccine produces a detectable 
level of viraemia. Although, measurable viraemia following vaccination is uncommon 
in adult animals with prior vaccinations (Paweska et al., 2003, Weyer et al., 2017). The 
LAV is useful for reducing the severity of the disease but vaccinated animals are still 
susceptible to the disease in field conditions and multiple vaccinations may be 
necessary for adequate protection (Molini et al., 2015).  
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Figure 1.4 - Transmission electron microscope photographs of AHSV particle from the 
vaccine (Image taken by Evan McColl). 
Attenuation through cell culture passage does not inhibit the vaccine-virus’ ability to 
infect the Culicoides vector (Venter et al., 2009). This has been demonstrated by AHS 
outbreaks shown to be caused by virulent reversion of vaccine strains transmitted by 
this vector (Weyer et al., 2016). Multivalent vaccines may increase the potential for 
reassortment by introducing multiple serotypes simultaneously (Mertens et al., 2005). 
Inactivated, or dead strain vaccines consist of virus particles that have been killed to 
prevent infection from the disease. Inactivated vaccines can effectively protect animals 
from AHS but multiple inoculations are needed as they do not confer a long-lasting 
immunity (House et al., 1994; Mellor & Hamblin, 2004; Lelli et al., 2013). Monovalent 
inactivated vaccines were used during the AHSV-4 epidemic in Spain, Portugal and 
Morocco that lasted from 1987-1991 (Zientara et al., 2015). Inactivated vaccines have 
the advantage of not causing viraemia, allowing vaccinated animals to be distinguished 
from naturally infected animals (House et al., 1994). 
For decades, vaccines for AHS have relied on attenuation or inactivation of the virus.  
The production of a new generation of vaccines that are safer and more stable is being 
made possible by advancements in recombinant DNA and peptide synthesis 
technology (Nascimento & Leite, 2012). Recombinant vaccines are produced through 
the insertion of an antigen-encoding gene into a carrier virus, which stimulates an 
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immunological response. Several new generation AHS vaccines are being investigated 
as safe alternatives to conventional vaccines (Guthrie et al., 2009, Alberca et al., 2014, 
Maree et al., 2016, Lulla et al., 2017).  
1.7. Diagnostics 
The disease can have devastating effects on serologically naïve horse populations, 
with mortality rates in some cases as high as 90% (Zientara et al., 2015). Clinical 
symptoms of AHS develop from problems with the circulatory and respiratory systems 
(Howell, 1962). The extent and severity of these symptoms categorise the disease into 
four separate forms (Table 1.2) (OIE, 2013). 
Table 1.2 - African horse sickness disease forms (Wohlsein et al., 1998; OIE, 2013; 
Zientara et al., 2015). 
Form 
Incubation 
period 
(days) 
Symptoms Prognosis 
Horse sickness 
fever 
5-14 Fever (39-40.5 ° C). 
Animal usually 
recovers 
Cardiac 7-14 
Fever (39-40 ° C). 
Swelling of eyelids, lips, 
cheeks, tongue, laryngeal 
region, fluid accumulation 
in the tissues. May shows 
signs of colic. 
Death usually occurs 
4-8 days following 
fever. 
Swelling lasts around 
6 days in recovering 
animals. 
Mortality > 50 % 
Pulmonary 3-5 
Fever (39-41 ° C). 
Respiratory problems 
characterised by severe 
shortness of breath. 
Frothy fluid often released 
from nostrils. 
Swelling around eyelids. 
Death from anoxia 
often occurs within 1 
week. 
Highly fatal especially 
in horses with low or 
no immunity.  
Cardio-pulmonary 
(mixed) 
3-14 
Fever (39-40 ° C). 
Mild pulmonary signs 
Fluid accumulation in the 
tissues. 
Death usually occurs 
3-6 days following 
fever. 
Mortality > 70 % 
Animals that manage to recover from the disease usually develop a strong immunity 
to that specific serotype but will still be susceptible to other serotypes (CFSPH, 2015). 
This poses a challenge in Sub-Saharan Africa where multiple AHSV serotypes exist 
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simultaneously and animals can be exposed to and introduce new serotypes when 
being relocated within a region (Weyer et al., 2016). Laboratory diagnosis of AHS is 
essential due to the similarity that the clinical signs have with other equine diseases 
(OIE, 2004). For example, equine encephalosis (EE) is caused by a closely related 
virus and share many clinical signs and epizootiological traits with AHS. 
An important component of accurate diagnosis is safe transportation and storage of 
suitable samples without significant damage. The preferred sample for the laboratory 
diagnosis of AHS is whole blood collected in an anti-coagulant (OIE, 2004). However, 
the cold chain infrastructure required for the transport of these samples is not available 
in rural and remote areas of AHS endemic regions. Alternative options need to be 
considered for collecting and storing biological samples. One such example is the use 
of dried blood spots (DBS) on filter paper, which has been shown to be successful at 
storing viral RNA at ambient temperature for subsequent nucleic acid assays (Alvarez-
Munoz et al., 2005, Uttayamakul et al., 2005).  
Confirmation of AHS is diagnosed through identification of the infectious virus, viral 
nucleic acids, viral antigens or specific antibodies (OIE, 2004). There are several 
published techniques available for AHS diagnosis. 
Viral neutralisation (VN) tests are the gold standard for AHSV isolation and serotyping 
(OIE, 2017). However, this serological test has the disadvantage of requiring the 
presence of AHSV antibodies, which are detectable between 10-14 days post infection 
(Zientara et al., 2015). This may make serological techniques unsuitable for outbreak 
management. Research into the diagnosis of AHSV has consequently shifted focus 
from VN techniques to nucleic-acid based assays, most notably PCR (Zientara et al., 
2015). 
1.7.1. PCR 
The Polymerase Chain Reaction (PCR) is a molecular technique for amplifying and 
detecting nucleic acid sequences (Mullis, 1987). This PCR amplifies specific regions 
of a DNA strand utilising two oligonucleotide primers that border the DNA sequence 
being amplified. The PCR is carried out in small reaction tubes that are placed into a 
thermal cycler controlling the temperature of the reaction. Controlled heating and 
cooling are carried out in cycles causing enzymatic replication of the nucleic acid 
segment between the two primer binding sites. A variant of PCR called reverse 
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transcription polymerase chain reaction (RT-PCR) is used to detect RNA sequences 
such as the AHSV genome. 
RT-PCR utilises the process of reverse transcription to transcribe RNA onto 
complementary DNA (cDNA) before being amplified in the following steps. Initially, RT-
PCR assays for the detection of AHSV were labour-intensive, requiring restriction 
fragment length polymorphism (RFLP) analysis followed by RT-PCR assays (Zientara 
et al., 1993). The first AHSV RT-PCR assays published targeted the VP3 (Sakamoto 
et al., 1994), VP7 (Sailleau et al., 1997), NS1 (Mizukoshi et al., 1994), NS2 (Stone-
Marschat et al., 1994) and NS3 genes (Zientara et al., 1998).  
The first serotype-specific RT-PCR assay involved the use of nine pairs of primers 
targeting genome Segment 2 (Sailleau et al., 2000). This segment encodes for VP2, 
which is the protein responsible for the antigenic variability between serotypes, and as 
such, most PCR genotyping assays target this gene (Weyer et al., 2015). Concerns 
have been raised with using the divergent genome Segment 2 as targets for PCR due 
to its propensity for genetic change (OIE, 2017). Diagnostic assays targeting this 
region would require periodic evaluation to ensure that genetic change does not render 
these assays obsolete. 
1.7.2. qPCR 
Real-time or quantitative PCR (qPCR) is a variation of PCR in which the thermal cycler 
can detect changes of reporter fluorophore signals during amplification. Intercalating 
dyes and fluorescent probes are detected by sensors and the fluorescence is plotted 
against the cycle number, creating an amplification plot (Fig. 1.5.)  
qPCR systems plot the accumulation of amplicons as the reaction takes place in real-
time, allowing for the quantification of the amplified product. This also eliminates the 
need for some post-PCR processing steps such as electrophoresis gel analysis for 
confirmation. This reduces the risk of cross-contamination and reduces the assay time.  
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Figure 1.5 – Simplified plot demonstrating the increase of fluorescence as cycle 
number increases during PCR amplification. 
To date, published RT-qPCR assays for AHSV target the VP2 (Weyer et al., 2015), 
VP7 (Aguero et al., 2008; Fernandez-Pinero et al., 2009; Quan et al., 2010), NS1 
(Rodriguez-Sanchez et al., 2008) and NS2 (Quan et al., 2010) genes.  
1.7.3. High-Resolution Melt 
High-resolution melt (HRM) analysis is molecular technique based on the release of 
intercalating dye from amplicons through controlled heating. The unique sequence of 
the amplicon determines the rate at which the dye is released so that different amplicon 
sequences can be distinguished from one another by relative differences in these rates 
(Ririe et al., 1997). 
Work by Groenink (2009 & 2014) focused on the development of an AHSV serotyping 
assay using HRM profiles from the PCR products of the nine serotypes. This approach 
used a primer pair to amplify a 181 bp region of Segment 10 and the generated HRM 
curves to group the sample into one of three bins. The serotype was then determined 
using Segment 2 clade-specific primers. This method was successful in correctly 
identifying the serotypes of viral reference strains and detected some reference strain 
anomalies, supported by the work of Weyer et al. (2015). 
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Accuracy and speed of detection of infectious diseases play a significant role in 
disease management. Early detection of the AHS serotype provides information 
needed for better and more efficient vaccination and control programs. Developments 
in speed and accuracy of AHS serotyping assays in combination with vaccination 
programs will aid in improving prophylaxis and control of this disease. 
1.8. Conclusion 
Control and diagnosis of AHS in endemic areas can be improved through improved 
sample handling techniques requiring less stringent transport conditions and safer 
vaccines. Effective prophylaxis of AHS is dependent upon good epidemiological 
models, early quarantining of viral ‘hot spots’, and measures that can be extended to 
vector control and good husbandry. Control of the disease will be improved by an 
increased understanding of the epizootiology and transmission of the disease. 
Therefore, improvements in the sensitivity, speed and accuracy of diagnostic assays 
will improve the effectiveness of control measures. 
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CHAPTER 2:  
A comparison of standard RT-PCR and RT-qPCR in the detection 
and quantification of AHSV 
2.1. Abstract 
African horse sickness (AHS) is a viral disease of equids caused by the African horse 
sickness virus (AHSV), a double-stranded RNA virus of the genus Orbivirus, which can 
devastate the sporting horse industry and the communities that rely on equids for 
subsistence farming. The diagnosis of AHS is often limited in endemic areas as 
diagnostics laboratories are under-equipped to perform the prescribed tests. Blood 
samples in EDTA were collected from horses in KwaZulu-Natal, South Africa. A semi-
quantitative method for PCR product analysis was evaluated against a standard qPCR 
assay as a potential alternative in under-equipped diagnostic laboratories. There was 
a significant correlation between qPCR data and relative gel quantification of AHSV 
(R2=0.768, P<0.01). With careful optimisation and calibrations, the assay described 
here could be useful where qPCR is not available. 
2.2. Introduction 
African Horse Sickness (AHS), caused by African Horse Sickness Virus (AHSV), is a 
vector-borne, infectious, non-contagious, often fatal viral disease affecting members of 
the Equidae family, with horses being the most susceptible (Zientara et al., 2015). The 
disease is vector-borne with Culicoides biting midges (Diptera: Ceratopognidae) being 
the primary vector. Due to the massive numbers of Culicoides in South Africa, vector 
control is not possible for complete control of AHS (Esterhuizen, 2015). Vaccination 
and movement control of equids are essential for AHS-control in South Africa. The 
movement of susceptible animals from endemic regions to areas free from the disease 
needs to be done with caution as an AHS outbreak could severely affect populations 
of serologically naïve animals (Robin et al., 2016). Accurate detection of AHSV is 
crucial for movement control measures to be effective. 
Reverse transcription-PCR (RT-PCR) was first used to detect AHSV in 1994 with a 
primer set targeting the NS2 gene (Stone-Marschat et al., 1994). Group-specific AHSV 
assays tend to target the more conserved genes: VP7 and NS2 (OIE, 2013). Real-time 
quantitative PCR (qPCR) allows for sensitive quantification of the target sequence 
without additional post-PCR work (Van Guilder et al., 2008). However, qPCR 
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capabilities are not standard in veterinary laboratories and may not be available for 
disease diagnostics in developing countries.  
 
The aim of this study was to evaluate the use semi-quantitative agarose gel data 
compared to a commercially available RT-qPCR kit (PrimerDesign, Southampton, 
United Kingdom) for the detection and quantification of AHSV from field samples. 
2.3. Materials and methods 
2.3.1. Sample population 
Whole blood samples were collected in ethylenediaminetetraacetic acid (EDTA) 
vacutainers from 81 horses in KwaZulu-Natal, South Africa. Prior to analysis, blood 
was frozen and stored at - 20 °C as it was convenient for storage until analysis (Quan 
et al., 2010).  
2.3.2. RNA Extraction 
Total RNA was extracted from blood samples using the Quick-RNA™ Miniprep Plus 
Kit (Zymo Research, Irvine, USA), according to the manufacturers’ recommendations. 
A volume of 500 µl of blood was transferred into a 2.5 ml microcentrifuge tube and an 
equal volume DNA/RNA Shield™ (2 X concentrate) was added to the sample. The 
mixture was vortexed before an 8 µl volume of Proteinase K (20 mg ml-1) was added 
and incubated at room temperature for 30 minutes. To this solution, 1 ml of isopropanol 
was added and vortexed. The mixture was transferred to a Zymo-Spin™ III-CG column 
and collection tube and centrifuged at 15,000 x g for 30 s. To this column, 400 µl RNA 
Prep Buffer was added, centrifuged at 15,000 x g for 30 s, and the eluent was 
discarded. The column was then washed twice with 700 µl RNA wash buffer and 
centrifuged at 15,000 x g for 2 minutes. The column was transferred to an RNase-free 
tube. The final RNA was eluted by adding 50 µl nuclease free water to the column 
followed by centrifugation at 15,000 x g for 30 s. RNA that was not used immediately 
was stored at -80 °C. Absorbance readings between the wavelengths of 220 and 
350 nm of the extracted RNA were taken using a NanoDrop 1000 (Thermo Fisher 
Scientific, Waltham, USA) to assess the quantity and purity of the extracted RNA. 
2.3.3. Complementary DNA (cDNA) synthesis 
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Reverse transcription was performed using the RevertAid First Strand cDNA Synthesis 
kit (Thermo Fisher Scientific, Waltham, USA). In a PCR tube, 2 µl of template RNA 
was added to 1 µl of random hexamer primer (100 µM) and 9 µl of nuclease-free water. 
This was incubated at 95 °C for 1 minute and immediately transferred onto ice. The 
mixture was combined with 4 µl of 5 X reaction buffer, 1 µl RiboLock RNase Inhibitor 
(20 U µl-1), 2 µl of 10 mM dNTP mix and 1 µl RevertAid M-MuLV Reverse Transcriptase 
(200 U µl-1). The mixture was vortexed, spun down and incubated at 25 °C for 
5 minutes followed by 42 °C for 60 minutes. The reaction was terminated by heating 
to 70 °C for 5 minutes. The cDNA was stored at -80 °C until further processing.  
2.3.4. Nucleic acid detection 
The PrimerDesign Genesig kit for AHSV VP7 detection was used in this study 
(PrimerDesign, Southampton, United Kingdom). The PCR was performed on a Rotor-
Gene™ 6000 (Qiagen, Hilden, Germany). 
Duplicate reactions were set up to a final volume of 20 µl containing 5 µl of template 
cDNA, 10 µl PowerUp™ Green Master Mix (Thermo Fisher Scientific, Waltham, USA), 
4 µl nuclease-free water and 1 µl AHSV specific primer/probe mix (PrimerDesign, 
Southampton, United Kingdom). The PCR reaction conditions were as follows: an 
initial Uracil-DNA Glycosylase (UDG) activation step of 50 °C for 2 minutes, 95 °C for 
2 minutes for initial denaturing, followed by 40 cycles of 95 °C for 5 s and 60 °C for 
30 s. Fluorescence data was collected at the end of each cycle.  
A positive control (PC) containing VP7 template DNA with a concentration of 
2x105 copies µl-1 was included in each PCR run. The concentration of the PC in each 
run was kept constant. Therefore, to have comparable results between runs the 
threshold value was set to a value where the PC had a Cq of 23.0 across all the PCR 
reactions. 
2.3.5. Agarose gel electrophoresis 
A volume of 5 µl of PCR product was run on a 1.8% (w/v) agarose gel in 1 X TBE buffer 
containing 1 X SYBR ® Safe DNA gel stain (Invitrogen, Carlsbad, USA) to determine 
the molecular weight of the PCR products. Electrophoresis was run at 6.66 V cm-1 for 
1 hour and visualised on a UV transilluminator. The DNA bands were sized using a 
GeneRuler™ 100 bp ladder marker (Thermo Fisher Scientific, Waltham, USA). The 
PCR band densities were digitally measured using ImageJ (Abramoff, 2004). 
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2.3.6. Standard curve generation 
To calculate viral count in test samples, a standard curve was generated using a serial 
dilution of VP7 template DNA ranging from 2 x 105 – 2 x 101 copies µl-1 as provided in 
the RT-qPCR kit. Each dilution was analysed in duplicate on a Rotor-Gene™ 6000 
using the Rotor-Gene™ 6000 series software.  
2.3.7. Analytical sensitivity 
Several methods for estimating qPCR assay sensitivity exist with no common 
consensus on the best method (Bustin et al., 2009). The limit of blank (LoB), limit of 
detection (LoD) and limit of quantification (LoQ) are important terms used to describe 
the level of analyte that can be reliably detected by an analytical assay (Clinical and 
Laboratory Standards Institute, 2004). The LoB is defined as the highest apparent 
concentration found for samples containing no target analyte. The LoD is the lowest 
concentration of analyte that can be reliably differentiated from the LoB. The LoQ is 
the lowest concentration of analyte that can be reliably quantified with an acceptable 
level of measurement variation.  For this study, the LoQ was determined to be the 
lowest concentration calibrant which fitted the linear section of the standard curve. LoB 
and LoD were determined according to Armbuster & Pry (2008) as shown below. 
LoB =  x̅ (𝑏𝑙𝑎𝑛𝑘)  + 1.645 × SD(𝑏𝑙𝑎𝑛𝑘) 
LoD = Lob + 1.645 × SD(𝑙𝑜𝑤 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑠𝑎𝑚𝑝𝑙𝑒) 
2.3.8. Statistical analysis 
The results of digital gel analysis were compared with the standard qPCR (Calibrated 
with external standards) by simple linear regression analysis. 
2.4. Results 
2.4.1. Electrophoresis gel analysis 
PCR products were run on electrophoresis gels to confirm product size (Fig. 2.1). Clear 
bands of the expected size of 118 bp were present in six samples (H35, H46, H48, 
H57, H58, H64). The PC included in each gel shows a clear band of the same size. 
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Contamination or large amounts of primer dimer result in some faint streaks visible 
around 100 bp and below in the gel image for samples H13-H24 shown in panel B (Fig. 
2.1.) The same streaks are seen in the NTC for that gel.  
 
Figure 2.1 - Analysis of RT-PCR products using VP7 primers to amplify a 118 bp: 
(A) H1-H12; (B) H13-H24; (C) H25-H36; A 1.8% agarose gel was stained with 
Invitrogen™ SYBR™ Safe DNA Gel Stain. Lane M - Thermo Scientific™ GeneRuler™ 
100bp DNA Ladder; Lanes H1-H71: Samples H1-H71; Lane PC: Positive control; Lane 
NTC: No template control. 
118 bp 
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Figure 2.1 cont. - (D) H37-H48; (E) H49-H60; (F) H61-H71.  
The gel images were analysed using ImageJ to quantify the band density of the PCR 
products. Table 2.1 shows the band density values after standardising them to the 
constant PC included in each gel. 
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Table 2.1 – Relative band density values as determined by digital electrophoresis gel 
analysis 
 
  
Sample Relative Band Density (%) Sample Relative Band Density (%) 
H1 6.24 H42 4.04 
H2 8.47 H43 2.60 
H3 0.61 H44 0.30 
H4 0.91 H45 0.42 
H5 1.26 H46 46.90 
H6 0.66 H47 8.17 
H7 0.66 H48 78.14 
H8 0.82 H49 0.37 
H9 0.53 H50 1.06 
H10 8.78 H51 1.08 
H11 7.55 H52 0.78 
H12 2.70 H53 0.04 
H13 2.86 H54 0.10 
H14 3.82 H55 0.07 
H15 4.13 H56 0.44 
H16 3.87 H57 39.93 
H17 4.98 H58 32.94 
H18 0.61 H59 1.79 
H19 4.74 H60 1.15 
H20 11.93 H61 0.35 
H21 3.20 H62 0.26 
H22 4.50 H63 0.83 
H23 2.09 H64 49.77 
H24 4.60 H65 0.98 
H25 3.06 H66 1.83 
H26 1.30 H67 2.44 
H27 0.74 H68 1.52 
H28 3.55 H69 1.43 
H29 4.27 H70 0.85 
H30 5.40 H71 1.41 
H31 10.28 H72 0.61 
H32 58.06 H73 1.18 
H33 0.55 H74 0.88 
H34 3.11 H75 0.70 
H35 3.05 H76 0.87 
H36 5.91 H77 0.68 
H37 1.67 H78 0.74 
H38 3.28 H79 0.97 
H39 6.24 H80 0.79 
H40 8.47 H81 0.97 
H41 0.61 PC 100.00 
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2.4.2. Standard curve 
Fig. 2.2 shows the graph of the fluorescence vs cycle number for the 10-fold dilution 
series. The fluorescence curves of the qPCR data in Fig. 2.2 show a delay in 
amplification take-off as the concentration of the template DNA decreases, with the 
longest delay being seen in the no template control (NTC). The variations in the 
fluorescence curves between replications increase as the number of copies in the 
template decrease. 
 
Figure 2.2 - Real-time PCR results for the amplification of a 10-fold dilution series for 
the generation of a standard curve. The plot represents cycle number vs fluorescence. 
Duplicate curves are represented by individual colours, representing a concentration 
range from 2 x 105 – 2 x 101 copies µl-1. No template controls (NTC) containing 
nuclease-free water in place of template were included. 
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The LoB and LoD were measured by using test replicates of samples known to contain 
no analyte and a low concentration of analyte, respectively. Since Cq-values are the 
observed measurement with the RT-qPCR assay, the Cq-values were used in the 
calculation of analytical sensitivity and could translate to copy number if required. The 
LoB was calculated to be 33.5. The LoD was then calculated at 32.5. Samples were 
regarded as AHSV positive if the Cq-value of the sample was below the LoD. 
A standard curve was constructed to measure the sensitivity of the qPCR assay and 
allow for quantification of samples (Fig. 2.3). The two lowest concentrations of the 
serial dilution (2 x 101 and 2 x 100 copies µl-1) are excluded from the standard curve 
generation as their Cq-values are not below the calculated LoD. Linear regression 
analysis performed on the data from linear range (2 x 105 – 2 x 102 copies µl-1) had an 
R2 > 0.99. Based on the slope of the curve, the PCR efficiency was calculated to be 
114%. The LoQ was determined to be the lowest concentration of the dilution series 
which fit the linear section of the standard curve. The LoB, LoD and LoQ are indicated 
on the curve. 
 
Figure 2.3 - Standard curve generated using 10-fold dilution series of external control 
of known concentration (2 x 105 copies µl-1). The plot represents Cq against the log 
concentration of the template. The two lowest calibrants (2 x 101 – 2 x 100 copies µl-1) 
which are not included in the standard curve generation are shown connected with a 
dotted line. The LoB (LoB; Cq = 33.5), LoD (LoD; Cq = 32.5) and LoQ (LoQ; Cq = 32.0) 
are annotated.  
The Cq-values reported are defined as the cycle number at which the normalised 
fluorescence intercepts the threshold. Fig. 2.4 shows the fluorescence data from the 
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Rotor-Gene™ 6000 software for the RT-qPCR of extracted RNA, using H48 and H49 
as examples of a positive and negative result respectively. Included in the figure are 
the amplification plots for the PC and NTC. The NTC and H49 have similar 
amplification curves with Cq-values above the LoD.  
 
H48 H49  NTC  PC 
Figure 2.4 - Rotor-Gene™ 6000 data for the amplification of the 118 bp region of AHSV 
Segment 7 extracted from H48 and H49 with Positive (PC) and No template controls 
(NTC). The LoD is indicated on the graph. 
The Cq-values for H1 - H81 are summarised in Table 2.2. The lowest Cq was 26.7 for 
H35. Six out of the 81 tested samples had Cq-values lower than the LoD of 32.5. The 
same samples had clear bands of expected product size on electrophoresis gels 
(Fig. 2.1). The mean Cq-value (± SD) for the NTC across the 3 separate runs was 
36 (± 1.0). 
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Table 2.2 - Quantification cycle (Cq) values of qPCR for sampled horses H1 - H81. N 
indicates that the fluorescence threshold was not reached.  
Sample Cq Sample Cq 
H1 37.8 H42 35.9 
H2 37.7 H43 36.0 
H3 37.1 H44 N 
H4 39.5 H45 34.8 
H5 36.7 H46 29.9 
H6 N H47 35.1 
H7 37.2 H48 30.1 
H8 39.0 H49 34.3 
H9 37.4 H50 N 
H10 37.0 H51 33.7 
H11 36.5 H52 36.0 
H12 35.6 H53 34.4 
H13 37.1 H54 35.0 
H14 36.3 H55 34.1 
H15 35.5 H56 36.2 
H16 N H57 31.4 
H17 N H58 30.7 
H18 34.8 H59 34.8 
H19 37.0 H60 35.3 
H20 35.5 H61 33.5 
H21 36.9 H62 34.6 
H22 36.4 H63 32.6 
H23 36.4 H64 31.1 
H24 36.3 H65 33.0 
H25 35.8 H66 33.0 
H26 34.8 H67 34.1 
H27 34.8 H68 36.8 
H28 34.9 H69 36.6 
H29 37.3 H70 33.9 
H30 35.2 H71 35.3 
H31 37.1 H72 34.0 
H32 37.8 H73 34.9 
H33 37.5 H74 33.0 
H34 39.0 H75 34.6 
H35 26.7 H76 33.5 
H36 37.2 H77 34.7 
H37 37.8 H78 34.3 
H38 37.5 H79 37.2 
H39 39.0 H80 36.0 
H40 33.3 H81 34.1 
H41 38.1 PC 23.0 
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2.4.3. Comparison of RT-qPCR and gel quantification 
Simple linear regression analysis was performed on the data of band density and Cq-
values for samples H1-H81. A clump of 75 data points included in panel A (Fig. 2.5), 
represent samples which were considered negative. These samples had low band 
density and high Cq-values. Linear regression analysis indicated there was a significant 
correlation between the qPCR data and the digital gel analysis data (P < 0.01) with an 
R2 = 0.556. Panel B of Fig. 2.5 is the simple linear regression with the negative results 
excluded and shows a higher coefficient of determination (R2 = 0.768). 
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Figure 2.5 – Simple linear regression analysis of threshold cycle value (Cq) vs. relative 
band density. A – All samples included in the regression analysis; B – Negative 
samples removed from the regression analysis 
2.5. Discussion 
The objective of this study was to evaluate the use of gel image analysis as a method 
for AHSV quantification of field-collected samples. A commercially available qPCR 
assay was used as a reference technique for comparison.  
A 
B 
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The gel images shown in Fig. 2.1 showed six cases of distinguishable bands of 118 bp. 
Some evidence of contamination or primer dimer is shown in panel B (Fig. 2.1), these 
samples are most likely negative as the band appears as more of a smear than a solid 
band, which would be expected after 40 amplification cycles of a specific region. A 
similar smear is seen in the NTC of the same gel.  
Digital analysis of these bands was performed using ImageJ, as described by 
Antiabong et al., (2016). The band density values produced using this method are 
measured relative to all the band densities in the included image. Therefore, measured 
values from samples on different gels cannot be directly compared and each laboratory 
would need to calibrate the procedure for their equipment. To account for variations 
between gels, the PC was used as a reference to calculate the relative band density 
as it was included in each gel at the same concentration. Additionally, all gels were run 
under identical conditions using the same equipment, settings and reagents. The 
relative band densities from different gels could then be normalised and compared. 
The ability to quantify bands is useful because it allows information that is stored in a 
gel image to be saved in a more condensed format. After 40 cycles, PCR amplification 
is likely to have reached a plateau making concentration differences in the original test 
samples less apparent. Optimisations such as terminating this reaction during the 
exponential amplification stage may provide more meaningful quantification data and 
need further investigation should this method be used in the future.  
For the RT-qPCR assay, a LoD had to be determined with the laboratory-specific 
conditions (Fig. 2.3). In some assays, a Cq cut-off value is determined to reduce the 
risk of interpreting a high Cq as a positive. If used, a Cq cut-off value should be 
specifically evaluated for different assays and PCR equipment to minimize the number 
of false positives and negatives. For this assay, a Cq cut-off corresponding to the 
observed LoD was selected (Cq-value > 32.5). Values higher than this indicated that 
the assay was unable to detect AHSV nucleic acid. Previous studies which have used 
this genome segment for quantification have generally used higher Cq cut-off values 
(Guthrie et al., 2013; Weyer et al., 2017). It is, however, difficult to compare Cq-values 
between laboratories using different equipment and reagents because these values 
are instrumental readings and not biologically meaningful (Bustin et al., 2009). The 
standard curve calibrated with external standards presented in Fig. 2.3 can be used to 
convert the laboratory-specific Cq-values to viral load. For this study, the SYBR green 
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intercalating dye bound to primer dimers, increasing background noise, which reduced 
the analytical sensitivity. With qPCR, the probability of false positive results increases 
as the analyte concentration approaches the LoD. For low viral titre, additional 
electrophoresis gel analysis may be required for confirmation. 
In total, six AHSV-positive samples were detected in the sampled population. The six 
samples with Cq-values lower than the LoD (Table 2.2) were the same six to have clear 
bands present on a gel at the same position as the positive control (Fig. 2.1). Digital 
analysis of electrophoresis gel images and the RT-qPCR assay showed a statistically 
significant relationship (P <0.01) in the quantity of amplified product (Fig. 2.5). There 
was a high degree of correlation (R2 = 0.768) between the results of the two methods. 
While qPCR is a more sensitive quantification tool than gel analysis (Schmittgen et al., 
2000), the method assessed above is a more affordable way to add valuable 
information to the conventional interpretation of PCR results by of gaining information 
on the relative quantity of amplified product. This may be particularly important in 
developing countries with veterinary laboratories lacking qPCR equipment. 
2.6. Conclusion 
Quantification using digital gel analysis will not replace the more sensitive qPCR 
assays but may prove to be a useful substitute in resource-limited settings with under-
funded diagnostic laboratories. The ability to quantify viral load improves empirical 
decision making with regards to disease control and management. 
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CHAPTER 3:  
Investigation of the effect of a commercial live attenuated vaccine 
on viral load in mares 
3.1. Abstract 
Vaccination is the main mechanism of control of African horse sickness (AHS) in 
endemic areas. Improvements to the sensitivity of nucleic acid diagnostic assays allow 
for the detection of low levels of African horse sickness virus (AHSV) prior to the onset 
of clinical signs. A limitation of these assays is that they may detect RNA from live 
attenuated vaccines (LAV). This experiment examined the effect of the vaccine on viral 
load using an RT-qPCR diagnostic assay. Routinely vaccinated miniature mares (n=9) 
had their AHSV viraemia levels monitored following vaccination with a live-attenuated 
vaccine. No AHSV was detected in the horses following vaccination. The absence of 
AHSV in the mares supports vaccination as a viraemia reduction strategy.  
3.2. Introduction 
Vaccination remains the most practical method for prevention of viral diseases. The 
World Organisation for Animal Health (OIE) lists African horse sickness (AHS) as 
important to international trade. Countries and zones free from the disease are officially 
recognised by the OIE affecting the movement of animals between these areas (OIE 
Code Commission, 2012). 
A live attenuated vaccine (LAV) manufactured by Onderstepoort Biological Products 
(OBP) is available in AHS endemic areas. This vaccine consists of two separate doses 
administered at least three weeks apart. The first vaccine contains Serotypes 1, 3, 4 
and the second contains Serotypes 2, 6, 7, 8. Cross-protection reportedly exists 
between AHSV-5 and AHSV-8, as well as, AHSV-6 and AHSV-9 (von Teichman et al., 
2010) therefore AHSV-5 and AHSV-9 are not included in either vaccine.  
For a vaccine strain to be accepted in South Africa it cannot cause viraemia levels of 
above 103 PFU ml-1 (Paweska et al., 2003). However, a problem arises because the 
level of viraemia needed to infect the Culicoides vector is unknown. Thus, it is not 
definitively known if the level of viraemia induced by vaccination is low enough to 
prevent transmission from host to vector. It has been recently reported that AHS-
vaccine virus has been transmitted through the normal AHS vectors (Weyer et al., 
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2016). In addition, the OBP AHSV-LAV has caused outbreaks of virulent AHSV 
through genetic re-assortment and reversion to virulence (Weyer et al., 2016), 
indicating that serologically naïve equids are at risk of contracting AHS by the 
movement of vaccinated horses into AHS-free zones. The use of the vaccine should, 
therefore, be limited to periods of low vector activity and if possible not used in AHSV 
free zones. 
Molecular diagnostics based on the amplification of nucleic acids, i.e, PCR and RT-
PCR, can rapidly detect the presence of the virus. This has a range of applications 
within infectious disease diagnostics and has been used to detect and serotype the 
AHSV (Sailleau et al., 2000). However, RT-PCR is unable to distinguish between the 
attenuated vaccine virus and natural infection which may result in false reporting of the 
disease in vaccinated animals (Weyer et al., 2017). 
In this study, a group of mares received vaccination with a commercial AHSV-LAV, 
and their viral load was monitored through RT-qPCR to determine if the AHSV-LAV 
could elicit detectable viraemia. 
3.3. Materials and methods 
3.3.1. Study population 
Routinely vaccinated miniature mares (n = 9) aged 6 - 12 years of age were used in 
this study. Horses were housed at University of KwaZulu-Natal (UKZN), Ukulinga 
Research farm in the KwaZulu-Natal, South Africa. Ethical approval for the blood 
retrieval from these animals was granted by the Animal Research Ethics Committee of 
UKZN (Appendix 1). 
3.3.2. Vaccination 
The horses were vaccinated with the Onderstepoort Biological Products (OBP) vaccine 
in two doses (Day 0 and Day 28), as per the manufacturer’s recommendations.  
3.3.3. Blood Collection 
Blood samples were collected in EDTA-containing vacutainers (Becton Dickinson, New 
Jersey, USA).  Blood samples were taken on vaccination days prior to blood collection 
and then as detailed in Fig. 3.1. The blood samples were placed on ice before being 
transported to the laboratory for processing. 
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Figure 3.1 - Timeline of sampling and vaccination program 
3.3.4. RNA Extraction 
Total RNA was extracted from blood samples using the Quick-RNA™ Miniprep Plus 
Kit (Zymo Research, Irvine, USA), according to the manufacturer’s recommendations: 
A volume of 500 µl of blood from each sample was transferred into a 2.5 ml 
microcentrifuge tube and an equal volume DNA/RNA Shield™ (2 X concentrate) was 
added to the sample and vortexed. An 8 µl volume of Proteinase K (20 mg ml-1) was 
added to each mixture and incubated at room temperature for 30 minutes. To this 
solution, a 1 ml aliquot of isopropanol was added and vortexed. The mixture was 
transferred to a Zymo-Spin™ III-CG column (Zymo Research, Irvine, USA) and 
collection tube and centrifuged at 15,000 x g for 30 s. To this column, 400 µl RNA Prep 
Buffer was added, centrifuged at 15,000 x g for 30 s, and the eluent was discarded. 
The column was then washed twice with 700 µl RNA wash buffer and centrifuged at 
15,000 x g for 2 minutes. The column was transferred to an RNase-free tube. The final 
RNA was eluted by adding 50 µl nuclease free water to the column followed by 
centrifugation at 15,000 x g for 30 s. RNA that was not used immediately was stored 
at -80 °C. Absorbance readings between the wavelengths of 220 and 350 nm of the 
extracted RNA were taken using a NanoDrop 1000 (Thermo Fisher Scientific, 
Waltham, USA) to assess the quantity and purity of the extracted RNA.  
3.3.5. Complementary DNA (cDNA) synthesis 
Reverse transcription was performed using the RevertAid First Strand cDNA Synthesis 
kit (Thermo Fisher Scientific, Waltham, USA). In a PCR tube, 2 µl of template RNA was 
added to 1 µl of random hexamer primer (100 µM) and 9 µl of nuclease-free water. 
This was incubated at 95 °C for 1 minute and transferred immediately onto ice. The 
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mixture was combined with 4 µl of 5 X reaction buffer, 1 µl RiboLock RNase Inhibitor 
(20 U µl-1), 2 µl of 10 mM dNTP mix and 1 µl RevertAid M-MuLV Reverse Transcriptase 
(200 U µl-1). The mixture was vortexed and incubated at 25 °C for 5 minutes followed 
by 42 °C for 60 minutes. The reaction was terminated by heating to 70 °C for 5 minutes. 
The complementary DNA (cDNA) was stored at -80 °C for further processing.  
3.3.6. Nucleic acid detection 
The detection of the AHSV VP7 gene was performed using the Genesig AHSV kit 
(PrimerDesign, Southampton, United Kingdom). The PCR for each sample was 
performed on a Rotor-Gene™ 6000 (Qiagen, Hilden, Germany). Duplicate reactions 
were set up to a final volume of 20 µl containing 5 µl of template cDNA, 10 µl 
PowerUp™ Green Master Mix (Thermo Fisher Scientific, Waltham, USA), 4 µl 
nuclease-free water and 1 µl AHSV specific primer/probe mix (PrimerDesign, 
Southampton, United Kingdom). The PCR reaction conditions were as follows: an 
initial Uracil-DNA Glycosylase (UDG) activation step of 50 °C for 2 minutes, 95 °C for 
2 minutes for initial denaturing, followed by 40 cycles of 95 °C for 5 s and 60 °C for 
30 s. Fluorescence data was collected at the end of each cycle.  
A positive control (PC) containing VP7 template DNA with a concentration of 
2 x 105 copies µl-1 was included in each PCR run. The concentration of the PC in each 
run was kept constant. Therefore, to have comparable results between runs the 
threshold value was set to a value where the PC had a Cq of 23.0 across all the PCR 
reactions. 
3.3.7. Agarose gel electrophoresis 
A volume of 5 µl of PCR product was run on a 1.8% (w/v) agarose gel in 1 X Tris-
borate-EDTA (TBE) buffer containing 1 X SYBR ® Safe DNA gel stain (Invitrogen, 
Carlsbad, USA) to determine the molecular weight of the PCR products. 
Electrophoresis was run at 6.66 V cm-1 for 1 hour and visualised on a UV 
transilluminator. The DNA bands were sized using a GeneRuler™ 100 bp ladder 
marker (Thermo Fisher Scientific, Waltham, USA).  
3.3.8. Standard curve 
To calculate viral quantity in test samples, a standard curve was generated from a 
known concentration of plasmid DNA provided as an external positive control (PC) with 
the PCR kit. The standard curve was generated using a 10-fold dilution series of the 
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template DNA ranging from 2 x 105 – 2 x 101 copies µl-1 The LoQ was determined as 
the lowest concentration of the serial dilution which fits on the linear range of the 
standard curve. LoB and LoD were determined according to Armbuster & Pry (2008). 
3.3.9. Data analysis 
Analysis of variance (ANOVA) was used to analyse the Cq differences over the study 
period. A P-value < 0.05 was considered significant.  
3.4. Results 
3.4.1. RNA extraction 
Spectrophotometric analysis of extracted RNA produced A260: A280 ratios in the range 
of 1.7 - 2.0. RNA quantity ranged from 12.0 – 65.5 ng µl-1. 
3.4.2. Analytic sensitivity 
The LoB and LoD were calculated using replicates of samples known to contain no 
analyte and low concentration of the analyte. No template controls (NTC) were 
included in each run alongside tested samples to test account for inter-run variation. 
Since Cq-values are the observed measurement with the RT-qPCR assay, the 
Cq-values were used in the calculation of analytical sensitivity and could translate to 
copy number if required. The LoB was calculated to be 33.4. The LoD was then 
calculated at 32.4. 
3.4.3. Nucleic acid detection 
Fig. 3.2 shows the gel image for the sample taken from Peppa on Day 0. Amplification 
products were detected for the PC (expected size of 118 bp), but no equivalent product 
was detected for any of the samples or NTC. No amplification products were detected 
on gels from the additional eight mares in the trial (data not shown). This demonstrates 
that there was no detectable AHSV RNA prior to vaccination. 
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Figure 3.2 - Analysis of RT-PCR products of Horse 5 (Peppa) amplifying a 118 bp 
fragment of the genome segment encoding VP7. A 1.8% agarose gel was stained with 
Invitrogen™ SYBR™ Safe DNA Gel Stain. Lane M: Thermo Scientific™ GeneRuler™ 
100bp Plus DNA; Lane 1 & 2: Horse 5 (Peppa); Lane 3: NTC; Lane 4: PC. 
Four runs in the Rotor-Gene 6000 were completed in total to analyse a total of 90 
samples. The ANOVA (Table 3.1) shows that there was no significant change in Cq-
values for the vaccinated adult mares between sampling periods (P > 0.05), indicating 
that there was no evident increase in the viral load following vaccination. 
Table 3.1 – Results of the ANOVA of standardized RT-qPCR Cq-values following 
vaccination of adult mares. 
ANOVA 
      
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 11.69717632 5 2.339435 1.043963 0.397924 2.33021 
Within 
Groups 177.0325813 79 2.240919 
          
Total 188.7297576 84         
 
 
±120 bp 
(expected 118 bp) 
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The line plot in Fig. 3.3 shows the mean and 95% confidence interval of Cq-values for 
the qPCR results of all horses across the 56-day period, indicating that no significant 
rise in AHSV occurred as all the means are within each other’s confidence interval. 
Samples with Cq-values lower than the LoD were classified as positive. 
 
Figure 3.3 - Line plot describing Cq-value distributions of the RT-qPCR targeting the 
VP7 gene of AHSV in adult mares following routine vaccination.  
The results showed that vaccination did not result in detectable levels of AHSV in the 
sampled animals. 
3.5. Discussion  
The aim of this study was to investigate whether the AHSV-LAV could elicit viraemia 
of a high enough level to be detected and quantified by RT-qPCR, and the potential 
this has for disrupting AHSV surveillance. All mares tested negative for AHS prior to 
vaccination (Fig. 3.2) and continued to test negative throughout the trial (Table 3.1 & 
Fig. 3.3). This result is supported by recent studies of viral load response in routinely 
vaccinated mares using the same vaccine (Weyer et al., 2017). However, in the work 
by Weyer et al., (2017), AHSV RNA was detected in weanling foals and yearlings for 
up to 16 weeks following vaccination. This is important because it shows that the LAV 
causes a considerable level of viremia in young animals. In addition to complicating 
surveillance, the vaccine virus may then be transmitted by the Culicoides vector to 
unvaccinated or susceptible animals. It has been demonstrated previously that in vitro 
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attenuation of AHSV may not eliminate the virus’s ability to infect the Culicoides vector 
(Venter & Paweska, 2007; Venter et al., 2009). In addition, the likelihood of vaccine 
virus reverting to virulence is increased by its ability to survive and multiply within the 
vector (Venter et al., 2009).  
The virulent reversion of AHSV-LAV was confirmed to be the cause of an AHS 
outbreak in South Africa in 2014, where recently vaccinated animals were moved into 
a serologically naïve area of the Western Cape (Weyer et al., 2016). Transmission of 
the virus was thought to have occurred through the normal Culicoides vectors. This 
exhaustive genetic analysis, which consisted of the sequencing and comparison of 
over 50 whole genomes, highlighted the importance of the continued development of 
alternative vaccines. Until these vaccines become commercially available the AHSV-
LAV will remain the mainstay for AHS control in endemic areas.  
The results reported in the present study indicate a low impact on the disease 
surveillance of previously vaccinated older animals. The age and vaccination history 
should be recorded when sampling and can be used to aid in interpreting RT-qPCR 
data. 
3.6. Conclusion 
The annually vaccinated mares in this study showed no signs of viral RNA in the weeks 
following immunization, confirming that vaccine-induced viraemia is low in previously 
vaccinated older horses. Information on the age and vaccination history of the animal 
is therefore important for the effective surveillance of AHSV and should be considered 
when analysing RT-qPCR data.  
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CHAPTER 4:  
The use of filter paper card technology in molecular African Horse 
Sickness Virus diagnostics 
 
Abstract 
Flinders Technology Associates® filter paper cards (FTA® cards) are designed to store 
nucleic acid from fresh sample material in a stable matrix. This may offer a practical 
solution to disease surveillance in resource-limited settings where conventional 
sampling methods are not always suitable. Storage and elution conditions of African 
horse sickness virus (AHSV) RNA from these cards was investigated. A pair of elution 
reagents for AHSV RNA extraction from blood applied to FTA® cards were compared. 
Cards with AHSV positive blood applied was stored at room temperature for one week. 
Amplified products were successfully detected by RT-PCR after elution with Tris-EDTA 
buffer. This work demonstrated that FTA® cards can be used to store and transport 
AHSV for RT-PCR analysis. 
4.1. Introduction 
RNA integrity is an important factor in obtaining and evaluating genomic information. 
Current sampling methods rely on an effective cold-chain which may be unavailable to 
under-equipped veterinary laboratories. Spoiled samples, degraded during 
transportation from remote areas to laboratories for analysis, may be difficult to 
distinguish from normal samples and will be processed as such. False negatives due 
to sample spoilage will cause underreporting of the disease. In the case of the often-
fatal AHS, a misdiagnosis could lead to the spread of the disease and subsequent 
equine deaths. 
The popularity of dried blood spots (DBS) in resource-limited settings for the detection 
of viral diseases is increasing because of the advantages they have over conventional 
sampling methods (Muthukrishnan et al., 2008; Sakai et al., 2015). Flinders 
Technology Associates (FTA®) cards are designed to store nucleic acid from fresh 
sample material in a stable matrix. The chemicals contained within the matrix denature 
unwanted proteins and lyse cells to release nucleic acids and may prove to be a good 
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alternative sampling technique in nucleic acid based assays for RNA viral detection 
(Sigma-Aldrich, 2017). An advantage with these cards is the inactivation of the virus, 
which allows for safe transport of non-infective samples while keeping the nucleic acid 
available for downstream analysis. This does, however, have limitations in that live 
virus particles cannot be isolated and cultured if required.  
FTA® cards have been used successfully in trials for the detection of viral RNA of Foot-
and-mouth disease virus (Muthukrishnan et al., 2008), rabies (Picard-Meyer et al., 
2007; Sakai et al., 2015) and Avian influenza virus (Abdelwhab et al., 2011, Jóźwiak 
et al., 2016). DBS samples have also been used for the detection of a related orbivirus, 
Bluetongue virus (BTV) (Martinelle et al., 2015). The use of FTA® cards for storage of 
blood for AHSV detection could reduce sample spoilage during transportation and 
storage, thus increasing the accuracy of testing and disease reporting.  
In this study, the use of FTA® cards was investigated as a method of storing blood for 
the detection of AHSV through RT-qPCR. The study compared methods for extracting 
AHSV RNA from FTA® cards.  
 
Figure 4.1 - Unused FTA® Micro Card 
4.2. Materials and methods 
4.2.1. Preparation of virus stored on FTA® cards 
FTA® classic and FTA® micro cards (Whatman/GE Healthcare Europe, Freiburg, 
Germany), were used for blood storage. To the cards, 200 µl of AHSV positive blood, 
previously identified through group-specific RT-qPCR, was added to the card sampling 
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area. The cards were stored in sealed foil envelopes at room temperature for one 
week.  
4.2.2. RNA Extraction 
Total RNA was extracted from blood samples using the Quick-RNA™ Miniprep Plus 
Kit (Zymo Research, Irvine, USA). Two different eluents were compared: TE-buffer (10 
mM Tris-HCl, 1 mM EDTA, pH 7.5) and RNA Lysis buffer (RL-buffer) (Zymo Research, 
Irvine, USA). RNA extractions were done in triplicate for the pair of eluents. Dried blood 
spots were cut out of each card using a scalpel and placed in nuclease-free 1.5 ml 
microcentrifuge tubes. To this, 300 µl of each eluent was added, mixed well and 
incubated at 4 °C for 24 hours. After 24 hours, the eluate was removed, placed into a 
Spin-Away Filter (Zymo Research, Irvine, USA) and centrifuged to remove gDNA. To 
the flow-through, 200 µl ethanol was added and mixed well. The mixture was 
transferred to a Zymo-Spin III-CG column (Zymo Research, Irvine, USA) in a collection 
tube and centrifuged at 15,000 x g for 30 s. To this column, 400 µl RNA Prep Buffer 
was added, centrifuged, and the flow-through was discarded. The column was then 
washed twice with 700 µl RNA wash buffer and centrifuged for 2 minutes. The column 
was transferred to an RNase-free tube and the final RNA was eluted by adding 30 µl 
nuclease free water to the column followed by centrifugation at 15,000 x g for 30 s.  
4.2.3. Complementary DNA (cDNA) synthesis 
Reverse transcription was performed using the RevertAid First Strand cDNA Synthesis 
kit (Thermo Fisher Scientific, Waltham, USA). In a PCR tube, 2 µl of template RNA 
was added to 1 µl of random hexamer primer (100 µM) and 9 µl of nuclease-free water. 
This was incubated at 95 °C for 1 minute and transferred immediately onto ice. The 
mixture was combined with 4 µl of 5 X reaction buffer, 1 µl RiboLock RNase Inhibitor 
(20 U µl-1), 2 µl of 10 mM dNTP mix and 1 µl RevertAid M-MuLV Reverse Transcriptase 
(200 U µl-1). The mixture was vortexed, spun down and incubated at 25 °C for 
5 minutes followed by 42 °C for 60 minutes. The reaction was terminated by heating 
to 70 °C for 5 minutes. The cDNA was stored at -80 °C for further processing. 
4.2.4. Nucleic acid detection 
The PrimerDesign Genesig kit for AHSV VP7 detection was used in this study 
(PrimerDesign, Southampton, United Kingdom). The PCR for each sample was 
performed on a Rotor-Gene™ 6000 (Qiagen, Hilden, Germany). Duplicate reactions 
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were set up to a final volume of 20 µl containing 5 µl of template cDNA, 10 µl 
PowerUp™ Green Master Mix (Thermo Fisher Scientific, Waltham, USA), 4 µl 
nuclease-free water and 1 µl AHSV specific primer/probe mix (PrimerDesign, 
Southampton, United Kingdom). The PCR reaction conditions were as follows: an 
initial Uracil-DNA Glycosylase (UDG) activation step of 50 °C for 2 minutes, 95 °C for 
2 minutes for initial denaturing, followed by 40 cycles of 95 °C for 5 s and 60 °C for 
30 s. Fluorescence data was collected at the end of each cycle. HRM was 
subsequently performed from 60 °C - 95 °C at 0.1 °C 2 s-1. 
A positive control (PC) containing VP7 template DNA with a concentration of 
2 x 105 copies µl-1 was included in each PCR run. The concentration of the PC in each 
run was kept constant. Therefore, to have comparable results with the standard curve, 
the threshold value was set to a value where the PC had a Cq of 23.0 the PCR 
reactions. 
4.2.5. Agarose gel electrophoresis 
A volume of 5 µl of PCR product was run on a 1.8% (w/v) agarose gel in 1 X TBE buffer 
containing 1 X SYBR® Safe DNA gel stain (Invitrogen, Carlsbad, USA) to determine 
the molecular weight of the PCR products. Electrophoresis was run at 6.66 V cm-1 for 
1 hour and visualised on a UV transilluminator. The DNA bands were sized using a 
GeneRuler™ 100 bp ladder marker (Thermo Fisher Scientific, Waltham, USA).  
4.3. Results 
No AHSV was detected with RT-qPCR when using elution times of 30 minutes. TE-
buffer and RLB (Zymo Research, Irvine, USA) then had their AHSV RNA elution 
capabilities compared when extending elution time to 24 hours at 4 °C.  
Fig. 4.2 shows the amplification plots of products from two different eluents. All the 
TE-buffer eluted samples amplified before the NTC while all the RL-buffer eluted 
samples amplified after the NTC, indicating that viral RNA could not be detected in the 
RLB eluted sample. 
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 RLB1.1    RLB1.2   RLB2.1   RLB2.2    RLB3.1    RLB3.2                                     
 TEB1.1    TEB1.2  TEB2.1    TEB2.2    TEB3.1     TEB3.2    NTC    PC 
Figure 4.2 - Rotor-Gene™ 6000 data for the amplification of the 118 bp region of AHSV 
Segment 7 extracted from dried blood spots. RLB - RNA Lysis Buffer; TEB – TE Buffer; 
NTC – No template control; PC – Positive control 
 
Cq-values obtained for the eluents used are summarised in Table 4.1. Samples with 
Cq-values < 32.5 were considered as AHSV positive. 
Table 4.1 - Cq for different eluents used for RNA extracted from FTA® cards 
Eluent Cq (± standard deviation) 
TE-buffer 1 29.69 (±0.08) 
TE-buffer 2 31.02 (±0.49) 
TE-buffer 3 32.16 (±0.13) 
RL-buffer 1 36.35 (±1.26) 
RL-buffer 2 35.35 (±0.68) 
RL-buffer 3 35.47 (±0.83) 
No template control 34.15 
Positive control 23.00 
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Amplified products had their product sizes confirmed by running a 1.8 % agarose gel 
in 1 X TBE (Fig. 4.3). Viral RNA eluted using TE-buffer yielded the expected bands of 
118 bp in all three tested samples after RT-qPCR (Lanes 1 - 3). No product was 
evident for the RL-buffer eluted samples (Lanes 4 - 6).  
 
Figure 4.3 - Analysis of RT-PCR products of AHSV RNA using VP7 primers to amplify 
a 118 bp product. A 1.8% agarose gel was stained with Invitrogen™ SYBR™ Safe 
DNA Gel Stain. Lane M - Thermo Scientific™ GeneRuler™ 100bp DNA; Lanes 1-3: 
TE-buffer; Lanes 4-6: RL-buffer; Lane 7 - PC; Lane 8: NTC. 
4.4. Discussion 
Two different eluents were evaluated for their ability to elute AHSV RNA from DBS on 
FTA® cards. RL-buffer is supplied with the Quick RNA Mini-Prep (Zymo Research) and 
although it is designed for cells, tissue and blood, it was unable to elute AHSV RNA 
from DBS on FTA® cards when following the manufacturer’s recommendations, and 
with the elution time increased to 24 hours. TE-Buffer is a non-proprietary, laboratory 
product and was found to be successful in eluting viral RNA from DBS on FTA® cards 
(Fig. 4.3). TE-Buffer has been found to be suitable for extracting viral RNA from DBS 
from Rabies virus and Human enterovirus (Li et al., 2012; Sakai et al., 2015).  
Picard-Meyes et al. (2007) reported successful elution of rabies virus using Dulbecco’s 
Modified Eagle Medium (DMEM) when the virus suspended in DMEM was applied to 
FTA® cards. The use of DMEM for elution of viral RNA from dried blood spots has, to 
the author’s knowledge, yet to be investigated. Another untested eluent which may 
prove useful is RNA Rapid Extraction Solution, the recommended eluent for RNA 
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extraction from FTA® cards. While TE-Buffer was successful, a more in-depth 
evaluation of eluents is necessary to determine the most suitable for the extraction of 
AHSV RNA. 
The FTA® cards used were stored at room temperature for 1 week before processing.  
Previous studies looking at storage conditions of FTA® cards on viral RNA degradation 
found significant RNA damage after 1 - 2 weeks of card storage at room temperature 
but found no damage after 3 months when the cards were stored at -20 °C or -80 °C 
(Sakai et al., 2015). The ability to transport biological samples from remote areas at 
room temperature without sample degradation increases regional access to diagnostic 
tests and reduces costs associated with cold chain shipment. 
A potential downside to DBS sampling is the low input volume which may be a concern 
for detecting low levels of virus.   
There is a lack of epizootiological data for many endemic regions affected by AHS. 
Improvement to the ease of collection and transport, together with greater safety and 
reliability of transporting biological samples using FTA® cards will improve 
epidemiological knowledge.  
4.5. Conclusion 
This study demonstrates that FTA® cards have the potential to be a powerful research 
tool for AHS. However, for viral load assays using dried blood spots to be comparable, 
standardised procedures for the collection, storage and extraction of viral RNA from 
these cards need to be established. It is unlikely that dried blood spots will replace the 
need for conventional sampling but may be useful to collect in addition to regular 
samples due to the relative sampling ease and demonstrated RNA stability. 
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CHAPTER 5:  
High resolution melt analysis of AHSV genome Segments 10 and 2  
5.1. Abstract 
African horse sickness (AHS) is caused by the African horse sickness virus (AHSV), a 
double-stranded RNA virus of the genus Orbivirus in the family Reoviridae. The viral 
genome is made up of ten double-stranded RNA segments. Nine antigenically different 
serotypes of AHSV have been identified so far. However, there is limited information 
on the serotype prevalence of AHSV in endemic areas. Therefore, multivalent vaccines 
remain the mainstay for disease control in these regions. In this experiment, a novel 
approach to assessing variations in AHSV nucleic acid using high-resolution melt 
analysis (HRMA) was investigated.  Blood infected with a wild strain of AHSV was used 
in a PCR targeting regions of Segment 10 (S10) and Segment 2 (S2). Following this, 
high-resolution melting curves were generated from these PCR products. S10 primers 
amplified the expected 181 bp product but the other primer sets failed to amplify the 
S2 gene segment warranting, further evaluation and optimisation of these primer sets 
used to detect currently circulating AHSV strains. 
5.2. Introduction 
The African horse sickness virus (AHSV) genome comprises ten double-stranded RNA 
segments each coding for at least one viral protein (Grubman & Lewis, 1992). Genome 
Segments 2 (S2) and 10 (S10) are responsible for the genetic diversity between 
serotypes and are usually the regions targeted by nucleic acid-based serotyping 
assays (Venter et al., 2002). The last of the antigenically different serotypes were 
isolated in 1960, indicating that AHSV is not a rapidly reassorting virus (Howell, 1962). 
Serotype determination is important in both epidemiological studies and vaccination 
programs. Sailleau et al. (2000) designed the first reverse transcription PCR (RT-PCR) 
assay for the serotyping of AHS. This assay targeted different regions of Segment 2 
according to the serotype using nine primer pairs in separate reactions. Confirmation 
of product was done on agarose gel electrophoresis. A recent assay developed in 
South Africa used three triplex AHSV real-time RT-PCR assays to identify individual 
serotypes (Weyer et al., 2015). This assay, although accurate, is costly due to the 
multiple fluorescent probes required.  
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High-resolution melt (HRM) is a fast, cost-effective and powerful post-PCR technique 
used to identify genetic variation. HRM uses precise heating of PCR product to release 
an intercalating dye that is measured through sensitive light detectors. The resulting 
melt curves that are generated can be used to detect differences in amplicon 
sequences. A serotyping assay for AHSV using HRM was investigated by Groenink. 
(2014). This assay uses a combination of S10 and S2 primers to determine serotype. 
The HRM profile generated from melting of the 10-190 bp region of S10 was used to 
group samples into one of three bins. The serotype was subsequently identified from 
these bins using melt curves obtained from Segment 2 clade-specific primers.   
The aim of this study was to test the primers sets described by Groenink (2014) on 
AHSV positive blood containing a currently circulating strain of AHSV to obtain a set 
of melt curves. 
5.3. Materials and methods 
5.3.1. Sample material 
For this assay to be used to serotype AHSV, reference HRM curves for the nine AHSV 
serotypes would need to be generated for the specific reagents and equipment used. 
Due to the lack of a complete reference strain set, HRM curves for field strains can be 
generated, but can not be used for serotyping. 
AHSV positive blood from two different horses, which had been identified previously 
by group-specific RT-qPCR was used for this study (H35 and H48). 
5.3.2. RNA Extraction 
Total RNA was extracted from the blood samples using the Quick-RNA™ Miniprep 
Plus Kit (Zymo Research, Irvine, USA), according to the manufacturer’s 
recommendations: A volume of 500 µl of blood from each sample was transferred to a 
2.5 ml microcentrifuge tube and an equal volume DNA/RNA Shield™ (2 X concentrate) 
was added to the sample and vortexed. An 8 µl volume of Proteinase K (20 mg ml-1) 
was added to each mixture and incubated at room temperature for 30 minutes. To this, 
1 ml of isopropanol was added and mixed by vortex. The mixture was transferred to a 
Zymo-Spin™ III-CG column (Zymo Research, Irvine, USA) in a collection tube and 
centrifuged at 15,000 x g for 30 s. To this column, 400 µl RNA Prep Buffer was added 
centrifuged at 15,000 x g for 30 s and the eluent was discarded. The column was then 
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washed twice with 700 µl RNA wash buffer containing ethanol and centrifuged at 
15,000 x g for 2 minutes. The column was then transferred to an RNase-free tube. 
Final RNA was resuspended by adding 50 µl nuclease free water to the column 
followed by centrifugation at 15,000 x g for 30 s. The eluted RNA was either used 
immediately or split up and stored at -80 °C. Absorbance readings between the 
wavelengths of 220 and 350 nm of the extracted RNA were taken using a NanoDrop 
1000 (Thermo Fisher Scientific, Waltham, USA) to assess the quantity and purity of 
the extracted RNA.  
5.3.3. Complementary DNA (cDNA) synthesis 
In a PCR tube, 2 µl of template RNA was added to 1 µl of random hexamer primer 
(100 µM) and 9 µl of nuclease-free water. This was incubated at 95 °C for 1 minute 
and transferred immediately onto ice. The mixture was combined with 4 µl of 5X 
reaction buffer, 1 µl RiboLock RNase Inhibitor (20 U µl-1) (Thermo Fisher Scientific, 
Waltham, USA), 2 µl of 10 mM dNTP mix and 1 µl RevertAid M-MuLV Reverse 
Transcriptase (200 U µl-1). The mixture was vortexed, spun down and incubated at 
25 °C for 5 minutes followed by 42 °C for 60 minutes. The reaction was terminated by 
heating to 70 °C for 5 minutes. The cDNA was stored at -80 °C for further processing. 
5.3.4. Primers 
Standard VP7 primers (PrimerDesign, Southampton, United Kingdom) were used to 
confirm the presence of AHSV RNA in the test samples. Table 5.1 describes the primer 
sets used in this study, as previously described by Groenink (2014).  
The S10 primers were designed to amplify a 181 bp product across all nine serotypes 
with differences in the amplicon sequences between primer binding sites depending 
on the serotype. These amplicon differences result in unique melt curves according to 
the serotype, allowing each sample to be placed into one of three clades (Table 5.2). 
A second set of primers, the clade-specific primers (A, B or C) can then be used to 
distinguish the serotype from the clade using discriminant analysis to compare the 
sample HRM data to reference data (Groenink, 2014). Due to the lack of reference 
strains, these melt curves would be generated but not used for serotyping. 
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Table 5.1 - List of primers used for the analysis of AHSV by HRM as defined in 
Groenink (2014) 
 
Name Sequence (5’-3’) 
Tm 
(°C) 
Size 
(bp) 
Segment 10 (S10) 
10F ATCCCTTGTCATGARTCTWGCT 
57.7 181 
10R CTTGACATKGCTTGRTTAAGTATCC 
Segment 2 (S2): Clade-
specific 
AF ATTCACYATGGCTTCKGA 
51.8 319 
AR CYACYCTTAYTTGRTTRTCATTTC 
BF TTGGGTTGAWTGGGTYGT 
54.9 249 
BR TTTGGRAACATYTGKGAWACDG 
CF AGYGGNTGGMTYCCDTA 
52.4 189 
CR CARTTYGARCCRATCCANG 
 
Table 5.2 - Serotypes per clade as defined in Groenink (2009) 
Clade Serotypes 
A 3, 7 
B 1, 2, 8 
C 4, 5, 6, 9 
  
5.3.5. Nucleic acid amplification 
The protocol was the following for all primer sets:  For a 20 µl reaction, 10 µl KAPA 
SYBR® FAST qPCR Master Mix (2 X), 0.8 µl forward and reverse primer (final 
concentration 400 nM), 6.4 µl nuclease-free water and 2 µl of cDNA template was 
combined in an extra-clear PCR tube. The tube was vortexed and spun down. The 
following PCR conditions were used: 95 °C for polymerase activation, followed by 40 
cycles of 95 °C for 5 s for denaturation and 60 °C for 30 s for annealing and extension. 
HRM was subsequently performed from 60 °C - 95 °C at 0.1 °C 2 s-1. PCR reactions 
were carried out in a Rotor-Gene™ 6000 (Qiagen, Hilden, Germany). 
5.4. Results 
PCR products for positive AHSV blood samples (Fig. 5.1) showed bands of suitable 
quality and size expected for both the VP7 and S10 regions.  
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Figure 5.1 - Analysis of RT-PCR products of AHSV RNA using primers to amplify a 
118 bp product of VP7 and a 181 bp product of S10. A 1.8% agarose gel was stained 
with Invitrogen™ SYBR™ Safe DNA Gel Stain. Lane M - Thermo Scientific™ 
GeneRuler™ 100bp DNA; Lane 1: H35 VP7; Lane 2: H48 VP7; Lane 3: PC VP7; Lane 
4 – NTC VP7; Lane 5: H35 S10; Lane 6: H48 S10.  
Fig. 5.2 is the graph of the normalised fluorescence from the qPCR of the cDNA from 
AHSV positive blood samples using the S10 primers. Amplification of product is shown 
from Cycle 22. The product was confirmed as being 181 bp by running a 1.8% agarose 
gel (Fig. 5.1). 
±180 bp 
(expected 
181 bp) 
±120 bp 
(expected 118 bp) 
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 - H35  - H48 
Figure 5.2 - Rotor-Gene™ 6000 data for the amplification of the 181 bp region of AHSV 
S10 extracted from AHSV positive samples using primers 10F and 10R. 
Figure 5.3 is the HRM curves generated from the 181 bp fragment of S10. The two 
samples have similar curves both with double melt peaks indicating that the amplicon 
sequences from both samples are similar. 
There was no amplification of either sample using primer sets A, B or C (data not 
shown). 
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 - H35  - H48 
Figure 5.3 - Real-time RT-PCR and HRM results for the 181 bp region of S10. A: 
HRM curve. B: dF dT-1 of HRM curve. 
 
5.5. Discussion 
An advantage in using random hexamer primers with the described protocol during 
cDNA synthesis, as recommended by Quan et al. (2010), is that the cDNA can be 
stored and used with multiple primer sets or other nucleic-acid studies if required. This 
may be important when analysing index cases in AHS-free zones as multiple PCR 
primer sets can be used on the same cDNA stock. In addition, as cDNA is more stable 
than viral RNA, it might be a more robust alternative to the long-term storage of RNA 
sequences (Huang et al., 2017). 
Primers outlined in this chapter (Table 5.1) were used in RT-PCR on selected AHSV 
positive blood samples. Internationally recognised VP7 primers were used as a 
A 
B 
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standard test to confirm the presence of AHSV RNA in these samples (Fig. 5.1). The 
S10 primers are designed to amplify a 181 bp region across all nine serotypes with 
differing sequences between the primer binding sites depending on the serotype. This 
allows HRM to detect differences in sequences of the amplified products that a gel 
would not be able to distinguish. S10 primers amplified a 181 bp region from both 
positive samples (Fig. 5.1). The successful amplification of target regions from both 
S10 and VP7 confirm the presence of AHSV. The HRM analysis of the 181 bp product 
revealed a double-peaked melt curve for each of the tested samples (Fig. 5.3b). This 
was most likely a result of multiple melt domains in the product because non-specific 
product amplification was not evident in the gel images (Fig. 5.1). The original study 
describing the primers only found double-peaked melt curves from serotypes in clade 
B (1, 2 or 8) (Groenink, 2014). Therefore, Clade B primers were expected to amplify a 
249 bp product. No amplification was evident when using any of the clade-specific 
primer sets on the AHSV cDNA (Data not shown).  
It is possible that sequence variation in genome Segment 2 prevented the amplification 
of the expected product. The successfully amplified regions (VP7 and S10) are 
reportedly more conserved and are unlikely to undergo significant genetic drift 
(Zientara et al., 2015). Bluetongue virus (BTV), the prototype species of the genus, 
has been extensively studied since its outbreak into Europe and 28 serotypes have 
been identified so far (Sun et al., 2016; Savini et al., 2017). Like AHSV, VP2 determines 
the serotype and is of relevance due to the increasing number of studies documenting 
the genetic reassortment of BTV (Shaw et al., 2013; Nomikou et al., 2015). 
There is also the possibility of a false positive caused by vaccine virus if the sampled 
horse was young and recently vaccinated. As the predominating vaccine used in South 
Africa is a multivalent vaccine, multiple serotypes would be present, all contributing the 
common genes (VP7 and S10), which are the targets for the group-specific assays. 
The serotype-specific (S2) genes would have been at a much lower level and may 
have been below the limit of detection. This result has been reported in previous AHSV 
serotyping studies where AHSV could be confirmed by VP7 confirmation but not 
serotyped by RT-qPCR targeting genome Segment 2 (Weyer et al., 2017). 
Several other avenues were investigated as to the reason for the failed PCR including 
retesting using different reagent sets and reordering the primers from multiple 
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suppliers. The original study which described and tested these primer sets worked with 
relatively pure AHSV isolated from cell culture supernatant as opposed to blood stored 
in EDTA. Additional optimisations for the use with blood-derived samples will have to 
be investigated more before further conclusions can be made. 
5.6. Conclusion 
Before more conclusions can be made regarding these primers, further investigations 
into optimisations of the assay on fresh blood-derived samples need to be undertaken. 
If possible, these samples should be sourced from reference laboratories and be of a 
known serotype to avoid the problems that arise from sourcing wild-type viruses.  
The possibility of genetic variation in Segment 2 of currently circulating field strains 
cannot be overlooked. Significant genetic variation in this genome segment is 
important because changes in it may result in several nucleic-acid based serotyping 
assays becoming obsolete or at least require re-evaluation.   
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Dissertation Overview 
African horse sickness (AHS) is a deadly disease affecting equids caused by African 
horse sickness virus (AHSV). The best practices for controlling AHS include 
vaccination and movement control. However, in epizootic outbreaks, these strategies 
do not provide adequate control. Molecular diagnostics of AHSV have proven to be 
successful in investigating previous outbreaks, but further development is needed for 
these tests to be useful in resource-limited endemic regions. There is also a growing 
concern regarding the use of live-attenuated vaccines in AHS control.  
The research presented in this dissertation aimed to address several components 
related to the molecular diagnostics of AHS: 1) To review and summarise the available 
literature relating to AHS molecular diagnostics; 2) To investigate viraemia levels 
following routine vaccination of mares; 3) To investigate the suitability of dried blood 
spot filter paper technology for the sampling of blood for AHSV detection; 4) Generate 
high resolution melt data on current AHSV strains as part of a potential serotyping 
assay.  
Chapter 2: A comparison of standard RT-PCR and RT-qPCR in the detection and 
quantification of AHSV 
Major findings: 
• There was a significant correlation between qPCR data and relative gel 
quantification of AHSV (R2=0.768, P<0.01).   
Implications: 
The correlation between the Cq-values and the relative band density suggests the 
technique may be a valuable tool in quantifying viral load of AHSV where qPCR 
equipment is not available. Further optimisation and lab-specific calibration are 
required if this protocol was to be used. 
Chapter 3: Investigation of the effect of a commercial live attenuated vaccine on 
viral load in mares 
Major findings: 
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• Mares in this study, which have been annually vaccinated, showed no signs of 
viral RNA in the weeks following immunization. 
Implications: 
No detectable viraemia in the adult mares suggests that there is low risk for the live-
attenuated vaccine to disrupt molecular diagnostics of AHS. Information on the age 
and vaccination history are therefore important considerations when analysing RT-
qPCR data.  
 
Chapter 4: Use of filter paper (FTA®) technology for sampling and recovery of 
African horse sickness virus RNA for molecular diagnostics 
Major findings: 
• Increasing the RNA elution time from 30 mins to 24 hours and using TE-buffer 
for RNA extraction allowed for the successful extraction of AHSV RNA.  
• AHSV RNA was detected from blood stored on FTA® cards for 1 week at room 
temperature. 
Implications: 
Dried blood spot filter paper technology may be useful for AHSV diagnostics, especially 
in remote endemic areas. The aim of this study was to develop a protocol for the 
storage and recovery of AHSV RNA from FTA cards. A combination of having a 24-
hour RNA elution time and using TE-buffer allowed for the successful extraction of 
AHSV RNA.  
 
Chapter 5: HRM analysis of melt curves 
Major findings: 
• AHSV was detected using a novel primer set, targeting genome 
Segment 10 (S10). This primer set has up until now not been used on wild 
AHSV RNA extracted from blood.  
• High-resolution melt curves were generated from the PCR products of the 
181 bp S10 fragment.  
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• There was no RT-qPCR amplification when using three type-specific primer sets 
designed to amplify regions of Segment 2.  
Implications: 
The failure of the RT-qPCR assay indicates that further research into this assay is 
required. Future work should address the following: 
• As this is the first study using this primer set on blood-derived samples, PCR 
conditions may be improved for these sample types.  
• There could be a substantial genetic variation in Segment 2 between the current 
wild-type AHSV strains and the reference strain sequences on which the 
primers were based. Genetic variation over time can cause antigenic 
differences in viruses which may also make current diagnostic assays obsolete. 
Revaluation of these primer sets may be necessary to be in line with current 
reference strain sequences. 
• The vaccination status and age of the animals from where the AHS positive 
blood originated was unknown. These may have been young animals receiving 
their first multivalent live-attenuated vaccine. If this was the case, conserved 
regions (VP7) which are present in all serotypes may have been detected by 
the standard RT-qPCR, but the serotype-specific regions (VP2), targeted by the 
primers used in this study, may have been below the limit of detection. If 
serotyped positive blood samples could be sourced from reference laboratories 
it will eliminate the problems that arise with sourcing these positive samples 
from wild cases. 
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Appendix 1 – Ethical clearance certificate for the vaccination trial at UKZN 
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Appendix 2 – Letter of no objection from state vet regarding AHS research in KwaZulu-
Natal  
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Appendix 3 – Permission to do research in terms of Section 20 of the Animal Diseases 
Act, 1984 (Act No 35 of 1984) 
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Table 3.2 - Group-specific RT-qPCR results for the mares over the 56-day study 
period. The Cq-value obtained for the NTC of that run is included. N indicates that the 
fluorescence threshold was not reached. 
Horse Name Sampling time (day) Cq Cq Replicate NTC Cq Positive Control Cq 
1. Thombi 
0 34.86 36.02 32.38 23.00 
7 36.72 37.26 32.38 23.00 
28 38.38 39.86 32.38 23.00 
35 N N 32.38 23.00 
56 N 39.10 32.38 23.00 
2. Flikka 
0 35.97 36.37 36.34 23.01 
7 34.05 35.26 36.34 23.01 
28 37.96 37.79 37.06 23.05 
35 37.28 37.59 37.06 23.05 
56 36.79 N 37.06 23.05 
3. Spikkle 
0 36.75 36.56 36.34 23.01 
7 34.74 36.69 36.34 23.01 
28 37.28 39.10 37.06 23.05 
35 37.48 37.07 37.06 23.05 
56 36.69 35.67 37.06 23.05 
4. Lily 
0 34.62 35.22 36.34 23.01 
7 34.43 35.88 36.34 23.01 
28 37.27 36.39 37.06 23.05 
35 35.68 N 37.06 23.05 
56 N 34.98 37.06 23.05 
5. Peppa 
0 34.08 35.31 36.34 23.01 
7 34.90 38.83 36.34 23.01 
28 37.19 35.58 37.06 23.05 
35 36.96 36.50 37.06 23.05 
56 36.48 36.51 37.06 23.05 
6. Paska 
0 36.31 34.43 36.35 23.01 
7 38.46 38.05 32.38 23.00 
28 35.89 34.84 37.06 23.05 
35 34.92 35.01 37.06 23.05 
56 N N 37.06 23.05 
7. Storm 
0 37.37 36.94 32.38 23.00 
7 37.61 36.44 32.38 23.00 
28 37.53 35.25 37.06 23.05 
35 37.26 37.97 37.06 23.05 
56 37.56 39.10 37.06 23.05 
8. Donkey 
0 38.02 37.50 32.38 23.00 
7 N 35.05 36.35 23.02 
28 34.11 36.76 36.35 23.02 
35 36.57 33.93 36.35 23.02 
56 35.29 34.00 36.35 23.02 
9. Zena 
0 34.95 33.03 32.38 23.00 
7 34.44 35.89 36.35 23.02 
28 34.09 35.32 36.35 23.02 
35 34.92 38.85 36.35 23.02 
56 36.32 34.45 36.35 23.02 
 
